# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.
Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism i...
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programsTREMFYA® is the only IL-23 inhibitor to ...
Johnson & Johnson faces a new class action lawsuit seeking damages and medical monitoring for cancer risk from talc products.
Johnson & Johnson announced that their Phase 3 GRAVITI study of Tremfya (guselkumab) SC therapy for Crohn's disease met...
Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...